Drug Profile
Budesonide/formoterol - Teva Pharmaceutical Industries
Alternative Names: BF Spiromax®; BiResp Spiromax; Budesonide/formoterol - Teva; Budesonide/formoterol fumarate dihydrate Spiromax®; DuoResp Spiromax; Formoterol/budesonide - Teva; Vylaer SpiromaxLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Teva Pharmaceutical Industries
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Bronchodilators; Ethanolamines; Glucocorticoids; Pregnenediones; Small molecules
- Mechanism of Action Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 12 Sep 2017 Launched for Asthma (In adults) and Chronic obstructive pulmonary disease (In adults) in South Korea, Israel, Russia (Inhalation) before September 2017
- 12 Sep 2017 Launched for Asthma (In adults) and Chronic obstructive pulmonary disease (In adults) in Slovenia, Netherlands, Latvia, Italy, France, Croatia, Bulgaria (Inhalation) before September 2017
- 31 Dec 2014 Launched for Asthma (In adults) in Spain (Inhalation)